AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04135534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group B
Description: mutonpain 0.1 mg/kg
Study NCT04135534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group C
Description: mutonpain 0.2 mg/kg
Study NCT00148798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab + cisplatin + vinorelbine
Description: cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Study NCT00148798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin + vinorelbine
Description: cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Study NCT04128553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention motivational interview group
Description: Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes.
Study NCT04089319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Music recording
Description: Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
Study NCT04089319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness recording
Description: Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
Study NCT00689741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 3 doses of IM injection
Study NCT00689741 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 doses of IM injection of Al(OH)3 placebo
Study NCT04040699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN026 combined with KN046
Description: KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
Study NCT00182819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
Study NCT00182819 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
Study NCT00782067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin (PKC412)
Description: Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
Study NCT02090881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
Study NCT02820415 — intervention group
Intervention type: OTHER
Intervention: chromosomal status of blastocysts from fresh and vitrified/warmed oocytes
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
Study NCT04421274 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT02200315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Antimicrobial prophylaxis
Description: Antimicrobial prophylaxis are not administered during an operation
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 70
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
Study NCT01526980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
Study NCT01295411 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Study NCT01295411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EVALUATION NEUROPSYCHOLOGICAL
Study NCT01395719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
Study NCT00795340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00795340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00795340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00795340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00795340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00795340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01345799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-170
Study NCT01345799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00574639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg given orally prior to morning and afternoon clamps on Day 1
Study NCT00574639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
Study NCT04111315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole Sodium
Description: Novalgin® Oblong tablets 0,5 g 2-2-2
Study NCT04111315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibufen-L® tablets 500 mg 2-2-2
Study NCT04111315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Leaflet and phone call
Study NCT01951950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Study NCT01951950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Study NCT03878511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
Study NCT03878511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
Study NCT02466061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Weight Management plus Wi-Fi Scale (Arm A)
Description: Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
Study NCT02466061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text for Diet (Text4Diet) Group (Arm B)
Description: Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
Study NCT02466061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Group (Arm C)
Description: Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
Study NCT03215966 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Macitentan / tadalafil FDC
Description: Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
Study NCT03215966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan (Opsumit®)
Description: Film-coated tablets for oral administration formulated at a strength of 10 mg
Study NCT03215966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil (Adcirca®)
Description: Film-coated tablets for oral administration formulated at a strength of 20 mg
Study NCT00625092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
Study NCT00625092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
Study NCT00625092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2
Study NCT00625092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
Study NCT01667471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Study NCT04161131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONBOARD
Description: Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
Study NCT02834637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types
Study NCT02834637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonavalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types
Study NCT00703638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
Study NCT00703638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
Study NCT00703638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: daily oral sorafenib (200 mg or 400 mg bid)
Study NCT00316563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol (Dronabinol)
Description: Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
Study NCT00316563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02012478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI- informed SMS program
Study NCT02193958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
Study NCT00883337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon β-1a
Description: Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®
Study NCT00883337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT00883337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT01592981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
Study NCT01592981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.
Study NCT01592981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.
Study NCT01592981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
Study NCT01592981 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
Study NCT01592981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
Study NCT03936504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group ：conventional exercise rehabilitation programs (CERP)
Description: The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
Study NCT03936504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)
Description: Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
Study NCT02743260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Study NCT02743260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02743260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Study NCT02743260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Study NCT02743260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Study NCT00763139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg by mouth once a day for 8 weeks
Study NCT00763139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: By mouth once a day for 8 weeks
Study NCT04135898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-04
Description: 3mg/kg, infusion in 90 minutes
Study NCT04135898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 3mg/kg, infusion in 90 minutes
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Threolone ointment
Description: ointment once daily for 1 month
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ointment Synthomycine
Description: ointment once daily for 1 month
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ointment Synthomycine
Description: ointment once daily for 1 month
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqua cream
Description: ointment once daily for 1 month
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqua cream
Description: ointment once daily for 1 month
Study NCT01256437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aqua cream
Description: ointment once daily for 1 month
Study NCT03049904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vr2L 2Spirit
Description: Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels.
Study NCT03726645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation
Study NCT03726645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation
Study NCT03828279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional and antigenic C1 inhibitor
Description: Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
Study NCT01146678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT01146678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT01146678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide AVE0010
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT01146678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide AVE0010
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT01617837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P6 acupressure band
Description: Comparison between groups 0-48 hours postoperatively.
Study NCT01617837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo band
Description: Comparison between groups 0-48 hours postoperatively
Study NCT02200380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: Related donors will receive CDX-301 for 5 days or 7 days.
Study NCT02200380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301 and plerixafor
Description: Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg or 100 mg tablet(s) administered orally once daily
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily